Post Transplant Lymphoproliferative Disorder risk factors in children: Analysis of a 23‐year single‐institutional experience. (4th June 2020)

• Record Type: Journal Article
• Authors: Bosse, Raphael C.; Franke, Aaron J.; Paul Skelton, William; Woody, Lindsey E.; Bishnoi, Rohit; Wang, Yu; Bhaduri‐McIntosh, Sumita; Rajderkar, Dhanashree; Shih, Renata; Dang, Nam H.; Slayton, William B.
• Is Part Of: Pediatric transplantation. Volume 24:Number 5(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-06-04
• Subjects: Epstein‐Barr virus -- pediatrics -- post‐transplant lymphoproliferative disorder -- solid organ transplant; Transplantation of organs, tissues, etc. in children -- Periodicals; 617.95408305
• DOI: 10.1111/petr.13747
• Languages: English
• ISSNs: 1397-3142

Abstract

Abstract: Introduction: PTLD is the most frequent malignancy following SOT in children and the second most common SOT complication in adults. However, factors determining outcomes in children are poorly understood due to its relative rarity. Methods: This study was performed at the University of Florida. Univariate and multivariate analyses were used to identify prognostic factors in pediatric patients diagnosed with PTLD. Results: We reviewed records of 54 pediatric (younger than 18 years old at diagnosis) patients diagnosed with PTLD from 1994 to 2017. The median follow‐up was 28.8 months. The estimated 5‐year survival rate was 87.6% (95% CI 74.3‐94.2%). Univariate analysis showed that organ transplanted (specifically heart transplant), poor response to initial treatment, allograft rejection, and low Karnofsky score were statistically significant for negative prognostic factors in determining survival. Multivariate analysis determined progression in response to initial treatment and presence of allograft rejection as statistically significant prognostic factors affecting overall survival. We found no statistically significant impact of EBV serological status on PTLD prognosis. Conclusions: Disease progression and allograft rejection were strong negative prognostic indicators in our study cohort. Close attention to graft status and development of therapies that protect the graft from rejection while bolstering anti‐EBV immunity will be essential to further improving PTLD outcomes in children.